Gefarnate

DB12079InvestigationalSmall molecule

Gefarnate has been investigated for the treatment and prevention of Stomach Ulcer, Duodenal Ulcer, and Cardio-cerebrovascular Disease.

Chemical structure of Gefarnate
Formula / weight
C27H44O2 · 400.647 g/mol (avg)
Code names
DA 688

Resolves to

Compound
UNII1ISE2Y6ULACAS51-77-4ChEMBLCHEMBL2105085ChEBI31646PubChem5282182
Clinical / RWD
ATCA02BX07ATCA02BX77
Structure
InChIKeyZPACYDRSPFRDHO-ROBAGEODSA-NSMILES[H]\C(CC\C(C)=C(/[H])CCC(=O)OC\C([H])=C(/C)CCC=C(C)C)=C(\C)CCC=C(C)C

What you can answer from here — as of February 21, 2021

4Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2ATC codesIncluding every combination product, plus 9 drug categories
Sign in

Which companies are running trials of Gefarnate, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In